Is bronchiectasis really a disease?
- PMID: 31996354
- PMCID: PMC9488738
- DOI: 10.1183/16000617.0051-2019
Is bronchiectasis really a disease?
Erratum in
-
"Is bronchiectasis really a disease?" Michal Shteinberg, Patrick A. Flume and James D. Chalmers. Eur Respir Rev 2020; 29: 190051.Eur Respir Rev. 2020 Feb 12;29(155):195051. doi: 10.1183/16000617.5051-2019. Print 2020 Mar 31. Eur Respir Rev. 2020. PMID: 32051170 Free PMC article. No abstract available.
Abstract
The definition of a disease requires that distinguishing signs and symptoms are present that are common, and that the constellation of signs and symptoms differentiate the condition from other causes. In bronchiectasis, anatomical changes, airways inflammation and airway infection are the distinguishing features that are common to this disease. However, bronchiectasis is a heterogenous disease: signs and symptoms are shared with other airway diseases, there are multiple aetiologies and certain phenotypes of bronchiectasis have distinct clinical and laboratory features that are not common to all people with bronchiectasis. Furthermore, response to therapeutic interventions in clinical trials is not uniform. The concept of bronchiectasis as a treatable trait has been suggested, but this may be too restrictive in view of the heterogeneity of bronchiectasis. It is our opinion that bronchiectasis should be defined as a disease in its own right, but one that shares several pathophysiological features and "treatable traits" with other airway diseases. These traits define the large heterogeneity in the pathogenesis and clinical features and suggest a more targeted approach to therapy.
Copyright ©ERS 2020.
Conflict of interest statement
Conflict of interest: M. Shteinberg reports grants, personal fees and other funding from GSK, grants and other funding from Novartis, other funding from Actelion, grants from Trudell pharma, personal fees from Astra Zeneca and Horizon Pharma, speakers fees from Teva, other from Rafa, and personal fees and other funding from Boehringer Ingelheim, outside the submitted work. Conflict of interest: P.A. Flume reports grants and personal fees from Bayer Healthcare AG and Insmed, grants from Novoteris, and personal fees from Eloxx Pharmaceuticals and Horizon Pharma, outside the submitted work. Conflict of interest: J.D. Chalmers reports grants and personal fees from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Grifols/Aradigm and Insmed, personal fees from Zambon, and personal fees from Novartis, Bayer, Napp and Savara, outside the submitted work.
References
-
- Marketos SG, Ballas CN. Bronchial asthma in the medical literature of Greek antiquity. J Asthma 1982; 19: 263–269. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources